Peter Pitts: Trump Should Negotiate Fair Trade, not Import Prescription Drugs
Importing prescription drugs from countries with price controls would keep costs high, reduce safety, and hinder innovation, argues former FDA Associate Commissioner Peter Pitts.
Former FDA Associate Commissioner Peter Pitts, president of the Center for Medicine in the Public Interest, says President Donald Trump's proposal to import prescription drugs from foreign countries would endanger patients. Diluted, expired, and counterfeit drugs would invade the U.S. drug market. Costs would be reduced only 1 to 2 percent. Drug manufacturers would no longer be able to endure bearing the burden of research and development, which they currently disproportionately bear. Instead, Trump should strut his negotiation skills, forcing other countries to pay their fair share, Pitts told Health Care News Managing Editor Michael Hamilton.